Galectin Therapeutics Inc Financials

GALT

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

1/9

Galectin Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.89x

For every $1 of reported earnings, Galectin Therapeutics Inc generates $0.89 in operating cash flow (-$41.8M OCF vs -$47.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-7.7x

Galectin Therapeutics Inc earns $-7.7 in operating income for every $1 of interest expense (-$42.4M vs $5.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Galectin Therapeutics Inc (GALT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$42.4M

YoY-11.5%

Galectin Therapeutics Inc's EBITDA was -$42.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.5% from the prior year.

Free Cash Flow

N/A

Net Income

-$47.0M

YoY-14.6%

Galectin Therapeutics Inc reported -$47.0M in net income in fiscal year 2024. This represents a decrease of 14.6% from the prior year.

EPS (Diluted)

$-0.76

YoY-2.7%

Galectin Therapeutics Inc earned $-0.76 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 2.7% from the prior year.

Cash & Debt

$15.1M

YoY-41.1%

5Y CAGR-20.5%

10Y CAGR-6.3%

Galectin Therapeutics Inc held $15.1M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

63M

YoY+2.1%

5Y CAGR+2.1%

10Y CAGR+11.0%

Galectin Therapeutics Inc had 63M shares outstanding in fiscal year 2024. This represents an increase of 2.1% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$36.6M

YoY+13.8%

5Y CAGR+37.4%

10Y CAGR+15.8%

Galectin Therapeutics Inc invested $36.6M in research and development in fiscal year 2024. This represents an increase of 13.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GALT Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$36.6M+13.8%	$32.1M+1.2%	$31.7M+33.2%	$23.8M+32.5%	$18.0M+140.7%	$7.5M
SG&A Expenses	$5.9M-1.3%	$5.9M-10.2%	$6.6M+4.0%	$6.4M+16.3%	$5.5M-8.4%	$6.0M
Operating Income	-$42.4M-11.5%	-$38.1M+0.7%	-$38.4M-27.1%	-$30.2M-28.7%	-$23.4M-74.5%	-$13.4M
Interest Expense	$5.5M+98.4%	$2.8M+170.3%	$1.0M+111.2%	$489K+462.1%	$87K0.0%	$87K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$47.0M-14.6%	-$41.1M-5.9%	-$38.8M-27.0%	-$30.5M-30.1%	-$23.5M-76.5%	-$13.3M
EPS (Diluted)	$-0.76-2.7%	$-0.74-13.8%	$-0.65-25.0%	$-0.52-26.8%	$-0.41	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.6M-19.9%	$3.3M-49.7%	$6.5M-14.6%	$7.6M-22.6%	$9.8M+21.8%	$8.1M	N/A	$7.7M
SG&A Expenses	$1.6M+16.3%	$1.4M-3.4%	$1.4M-4.0%	$1.5M-0.5%	$1.5M-7.3%	$1.6M	N/A	$1.4M
Operating Income	-$4.2M+9.2%	-$4.6M+41.4%	-$7.9M+12.9%	-$9.1M+19.7%	-$11.3M-17.0%	-$9.6M	N/A	-$9.2M
Interest Expense	$1.8M-0.3%	$1.8M+4.7%	$1.7M+16.7%	$1.5M+17.7%	$1.3M+20.6%	$1.1M	N/A	$835K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$8.2M-8.8%	-$7.5M+21.9%	-$9.6M+14.2%	-$11.2M+9.3%	-$12.4M-7.7%	-$11.5M	N/A	-$10.4M
EPS (Diluted)	$-0.13-8.3%	$-0.12+20.0%	$-0.15+16.7%	$-0.18+10.0%	$-0.20-5.3%	$-0.19	N/A	$-0.24

GALT Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$17.5M-38.0%	$28.2M+32.5%	$21.3M-49.1%	$41.8M+41.3%	$29.6M-38.9%	$48.5M
Current Assets	$17.3M-37.7%	$27.7M+34.8%	$20.6M-50.9%	$41.8M+41.9%	$29.5M-38.9%	$48.2M
Cash & Equivalents	$15.1M-41.1%	$25.7M+38.0%	$18.6M-53.1%	$39.6M+46.1%	$27.1M-42.8%	$47.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$120.6M+36.3%	$88.4M+65.4%	$53.5M+36.4%	$39.2M+625.2%	$5.4M+88.3%	$2.9M
Current Liabilities	$35.4M+125.9%	$15.7M+20.5%	$13.0M+44.0%	$9.0M+67.3%	$5.4M+91.5%	$2.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$104.8M-69.1%	-$62.0M-82.7%	-$33.9M-3898.1%	$893K-96.0%	$22.5M-48.8%	$43.9M
Retained Earnings	-$401.6M-13.3%	-$354.4M-14.5%	-$309.6M-14.4%	-$270.7M-12.8%	-$240.0M-10.9%	-$216.4M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$12.9M-17.5%	$15.6M+63.7%	$9.5M-45.5%	$17.5M-36.7%	$27.7M+6.8%	$25.9M-8.2%	$28.2M+27.2%	$22.2M
Current Assets	$12.7M-17.5%	$15.4M+66.1%	$9.3M-46.2%	$17.3M-36.8%	$27.3M+7.2%	$25.5M-8.1%	$27.7M+28.2%	$21.6M
Cash & Equivalents	$11.5M-16.3%	$13.8M+85.3%	$7.4M-50.9%	$15.1M-40.9%	$25.6M+8.7%	$23.6M-8.2%	$25.7M+26.0%	$20.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$136.4M+2.8%	$132.8M+9.0%	$121.8M+1.0%	$120.6M+9.8%	$109.8M+56.3%	$70.3M-20.6%	$88.4M+21.1%	$73.0M
Current Liabilities	$136.4M+1166.4%	$10.8M-90.3%	$110.8M+213.0%	$35.4M+142.2%	$14.6M+15.7%	$12.6M-19.4%	$15.7M+49.0%	$10.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$125.3M-5.4%	-$118.9M-4.3%	-$114.0M-8.8%	-$104.8M-24.9%	-$83.9M-89.0%	-$44.4M+28.4%	-$62.0M-17.8%	-$52.6M
Retained Earnings	-$427.0M-2.0%	-$418.8M-1.8%	-$411.2M-2.4%	-$401.6M-6.2%	-$378.3M-3.4%	-$365.9M-3.2%	-$354.4M-2.9%	-$344.3M

GALT Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$41.8M-26.7%	-$33.0M-6.1%	-$31.1M-27.8%	-$24.3M-18.0%	-$20.6M-89.9%	-$10.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	$0	$0	$0	N/A
Financing Cash Flow	$31.2M-22.0%	$40.0M+300.3%	$10.0M-72.8%	$36.8M+13897.7%	$263K-99.5%	$50.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$3.5M+46.3%	-$6.6M+14.1%	-$7.7M+39.9%	-$12.8M-53.5%	-$8.3M+31.2%	-$12.1M-157.4%	-$4.7M+38.4%	-$7.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$1.3M-90.0%	$12.9M	$0-100.0%	$851K-91.8%	$10.4M+3.8%	$10.0M0.0%	$10.0M-0.3%	$10.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GALT Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-268.9%-123.3pp	-145.6%+36.6pp	-182.2%-109.2pp	-73.0%+6.3pp	-79.3%-51.8pp	-27.4%
Current Ratio	0.49-1.3	1.77+0.2	1.58-3.1	4.63-0.8	5.46-11.6	17.10
Debt-to-Equity	-1.15+0.3	-1.43+0.1	-1.58-45.5	43.91+43.7	0.24+0.2	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-63.6%-15.4pp	-48.2%+52.9pp	-101.1%-62.3pp	-38.7%+6.0pp	-44.7%-0.4pp	-44.4%	N/A	-47.0%
Current Ratio	0.09-1.3	1.43+1.3	0.08-0.4	0.49-1.4	1.87-0.1	2.02+0.2	1.77-0.3	2.05
Debt-to-Equity	-1.09+0.0	-1.12-0.0	-1.07+0.1	-1.15+0.2	-1.31+0.3	-1.58-0.2	-1.43-0.0	-1.39
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$104.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.49), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

AUTOLUS THERAPEUTICS PLC AUTL

$372.6M

Diamedica Therapeutics Inc DMAC

$444.2M

Vigil Neuroscience, Inc. VIGL

$375.7M

Benitec Biopharm BNTC

$355.6M

Larimar Therapeutics Inc LRMR

$261.7M

Frequently Asked Questions

Is Galectin Therapeutics Inc profitable?

No, Galectin Therapeutics Inc (GALT) reported a net income of -$47.0M in fiscal year 2024.

What is Galectin Therapeutics Inc's earnings per share (EPS)?

Galectin Therapeutics Inc (GALT) reported diluted earnings per share of $-0.76 for fiscal year 2024. This represents a -2.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Galectin Therapeutics Inc's EBITDA?

Galectin Therapeutics Inc (GALT) had EBITDA of -$42.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Galectin Therapeutics Inc's operating cash flow?

Galectin Therapeutics Inc (GALT) generated -$41.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Galectin Therapeutics Inc's total assets?

Galectin Therapeutics Inc (GALT) had $17.5M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Galectin Therapeutics Inc spend on research and development?

Galectin Therapeutics Inc (GALT) invested $36.6M in research and development during fiscal year 2024.

How many shares does Galectin Therapeutics Inc have outstanding?

Galectin Therapeutics Inc (GALT) had 63M shares outstanding as of fiscal year 2024.

What is Galectin Therapeutics Inc's current ratio?

Galectin Therapeutics Inc (GALT) had a current ratio of 0.49 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Galectin Therapeutics Inc's debt-to-equity ratio?

Galectin Therapeutics Inc (GALT) had a debt-to-equity ratio of -1.15 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Galectin Therapeutics Inc's return on assets (ROA)?

Galectin Therapeutics Inc (GALT) had a return on assets of -268.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Galectin Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Galectin Therapeutics Inc (GALT) had $15.1M in cash against an annual operating cash burn of $41.8M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Galectin Therapeutics Inc's debt-to-equity ratio negative or unusual?

Galectin Therapeutics Inc (GALT) has negative shareholder equity of -$104.8M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Galectin Therapeutics Inc's Piotroski F-Score?

Galectin Therapeutics Inc (GALT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Galectin Therapeutics Inc's earnings high quality?

Galectin Therapeutics Inc (GALT) has an earnings quality ratio of 0.89x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Galectin Therapeutics Inc cover its interest payments?

Galectin Therapeutics Inc (GALT) has an interest coverage ratio of -7.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.